Week In Review: China's Innovent And Lilly Form $456 Million Cancer Biologics Alliance

Innovent Biologics, a four-year-old Suzhou biopharma, announced a very broad ten-year cross-border collaboration with Eli Lilly that includes as many as six potential biologic cancer treatments . Lilly will make a $56 million upfront payment, with milestones for a single immuno-oncology drug candidate totaling $400 million.

http://ift.tt/1HiOdk0